<SEC-DOCUMENT>0000950103-23-009306.txt : 20230627
<SEC-HEADER>0000950103-23-009306.hdr.sgml : 20230627
<ACCEPTANCE-DATETIME>20230627082239
ACCESSION NUMBER:		0000950103-23-009306
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230627
FILED AS OF DATE:		20230627
DATE AS OF CHANGE:		20230627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AC Immune SA
		CENTRAL INDEX KEY:			0001651625
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37891
		FILM NUMBER:		231044023

	BUSINESS ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
		BUSINESS PHONE:		41 21 345 91 21

	MAIL ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp195769_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR<BR>
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of June, 2023</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission file number: 001-37891</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EPFL Innovation Park<BR>
Building B<BR>
1015 Lausanne, Switzerland</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 27, 2023, AC Immune SA issued a press release announcing that
it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid beta (Abeta)
active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer&rsquo;s disease (AD). This follows FDA clearance of the
Investigational New Drug (IND) application enabling expansion to the USA of the ongoing Phase 1b/2 ABATE study of ACI-24.060 in patients
with AD and individuals with Down syndrome (DS). Furthermore, the first individual with DS has been dosed in ABATE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ACI-24.060&rsquo;s
Fast Track designation and IND clearance, as well as the expansion of ABATE to include individuals with DS were supported by positive
initial interim safety and immunogenicity data from ABATE&rsquo;s first, low dose AD cohort. Dosing in a second, higher dose AD cohort
began earlier this year. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Report on Form 6-K (other than Exhibit 99.1 hereto) shall be deemed
to be incorporated by reference into the registration statements on Form F-3 (File No. 333- 255576, File No. 333-227016 and File No. 333-249655)
and Form S-8 (File No. 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent
not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 7%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Exhibit
Number</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 93%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Description</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 12pt"><FONT STYLE="font-size: 10pt">Press Release dated June 27, 2023</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>AC IMMUNE SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Andrea Pfeifer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Andrea Pfeifer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Christopher Roberts</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Christopher Roberts</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Vice President, Finance and Interim Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Date: June 27, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp195769_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 48%; text-align: left; font-size: 12pt; font-weight: bold"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 48.4pt; width: 155.2pt"></TD>
    <TD STYLE="vertical-align: top; width: 18%; text-align: left; font-size: 12pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 34%">
    <P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 5.65pt 0pt 0; text-align: right"><FONT STYLE="text-transform: uppercase">Press
    Release </FONT></P>
    <P STYLE="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 5.65pt 0pt 0; text-align: right">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>AC Immune Receives FDA Fast Track Designation
for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer&rsquo;s Disease</B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites in USA
with Investigational New Drug (IND) clearance for ACI-24.060</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Dosed first individual with Down syndrome (DS) in the DS cohort of ABATE </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Interim safety and immunogenicity data in Alzheimer&rsquo;s disease (AD) and
DS cohorts expected in H2 2023</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Initial PET data on amyloid plaque reduction in AD expected H1 2024</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Lausanne, Switzerland, June 27, 2023</B> &ndash;
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases,
today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid
beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer&rsquo;s disease. This follows FDA clearance
of the Investigational New Drug (IND) application enabling expansion to the USA of the ongoing Phase 1b/2 ABATE study of ACI-24.060 in
patients with AD and individuals with DS. Furthermore, the first individual with DS has been dosed in ABATE.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Dr.&nbsp;Andrea Pfeifer, CEO&nbsp;of</B>&nbsp;<B>AC
Immune SA, commented:</B>&nbsp;&ldquo;We are delighted to see the quality and importance of our ACI-24.060 program reflected in the granting
of Fast Track designation, which offers opportunities for expedited development and regulatory review. This regulatory progress underscores
the attraction of an active immunotherapy targeting toxic species of Abeta. By inducing a polyclonal response including antibodies against
both oligomeric Abeta and pyroglutamate-Abeta, ACI-24.060 targets the same toxic species as disease modifying anti-Abeta monoclonal antibodies
that slowed AD progression in Phase 3 clinical trials. As ACI-24.060, created using our SupraAntigen<SUP>&reg;</SUP> platform, specifically
targets the most toxic forms of Abeta, we believe it may offer best-in-class efficacy with all the potential advantages in safety, administration
and distribution that can be expected from a vaccine. We look forward to showing in H1 2024 the effect of ACI-24.060 on amyloid plaque
reduction, a surrogate marker for disease modification.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">ACI-24.060&rsquo;s Fast Track designation and IND
clearance, as well as the expansion of ABATE to include individuals with DS were supported by positive initial interim safety and immunogenicity
data from ABATE&rsquo;s first, low dose AD cohort. Dosing in a second, higher dose AD cohort began earlier this year.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Dr. Johannes Streffer,
CMO of&nbsp;AC Immune SA, commented:&nbsp;</B>&ldquo;ABATE&rsquo;s expansion into the USA will allow us to accelerate the trial&rsquo;s
advancement and build upon the strong momentum we&rsquo;ve generated in Europe. With today&rsquo;s announcement, we remain firmly on track
to report additional interim safety and immunogenicity data later this year, and for the crucial interim readout of </P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> / 4&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">Abeta-PET imaging data in AD
in the first half of next year. By benchmarking the amount of Abeta plaque reduction achieved with ACI-24.060 against those achieved with
FDA-approved monoclonal antibodies, we believe we can generate early evidence of our vaccine&rsquo;s therapeutic potential to support
its expeditious advancement towards pivotal programs in AD and DS-related AD.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Dr. Michael Rafii, Medical Director of the Alzheimer&rsquo;s
Therapeutic Research Institute, Professor of Neurology at the Keck School of Medicine, and the Principal Investigator of the trial commented:</B>
&ldquo;Despite representing the world&rsquo;s largest population that is genetically at high risk for AD, individuals with DS are vastly
underserved and underrepresented in clinical trials. I applaud AC Immune for seeking to address the urgent needs of this population and
believe ACI-24.060 holds great promise as a novel therapy that can lower Abeta plaques to delay, or perhaps even prevent, the onset of
clinical dementia symptoms in AD and DS-related AD. Moreover, I believe the potential safety, efficacy, and logistical advantages of a
vaccine over monoclonal antibodies strongly support the development of therapeutics such as ACI-24.060 as the next generation of anti-Abeta
therapies.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About the Phase 1b/2&nbsp;ABATE&nbsp;Study&nbsp;(<FONT STYLE="color: Blue"><U>ClinicalTrials.gov</U></FONT>&nbsp;Identifier:
NCT05462106)</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The ABATE study is a Phase 1b/2, multicenter, adaptive,
double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, and pharmacodynamic effects of
ACI-24.060 in subjects with prodromal Alzheimer&rsquo;s disease and in adults with Down syndrome. All participants in the trial must have
brain Abeta pathology confirmed by a positron emission tomography (PET) scan. Recent clinical studies and FDA approvals have validated
Abeta as a disease modifying therapeutic target in AD and are supportive of Abeta PET imaging as a surrogate marker of efficacy. The trial
begins with a dose escalation phase in AD patients, during which various doses/dosing regimens may be evaluated, and also includes individuals
with DS.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About AD in Down syndrome</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Individuals with Down syndrome (DS) have a third
copy of all or part of chromosome 21, which contains the gene that codes for amyloid-precursor protein (APP). Overproduction of APP is
believed to cause the accumulation of Abeta plaques. Virtually all individuals with DS will develop Abeta plaques and AD<SUP>1</SUP>,
with DS-related AD sharing a similar pathophysiology and biomarkers with other forms of genetic AD. Given the more predictable onset and
progression of symptoms in DS-related AD, AC Immune believes ABATE&rsquo;s results will offer crucial insights into the ability of ACI-24.060
active immunotherapy to modulate neurodegeneration at its earliest stages and offer this population a much needed therapeutic option.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About ACI-24.060</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">ACI-24.060, derived from AC Immune&rsquo;s SupraAntigen&reg;&nbsp;platform,
has been shown in preclinical studies to induce a strong polyclonal antibody response that matures and is maintained against both oligomeric
and pyroglutamate-Abeta species, key pathological forms of Abeta believed to drive Abeta plaque formation and disease progression. ACI-24.060
is designed to enhance the formation of broad-spectrum protective antibodies with the same safety and tolerability previously demonstrated
in the ACI-24 program in Phase 1 and 2 trials. This investigational candidate has the</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> / 4&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">potential to efficiently inhibit plaque formation
and increase plaque clearance, and thereby may reduce or prevent disease progression.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Reference</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Lott, Ira T., and Elizabeth Head. &quot;Dementia in Down syndrome: unique insights for Alzheimer disease
research.&quot; <I>Nature Reviews Neurology</I> 15.3 (2019): 135-147.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About AC Immune SA
</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">AC Immune SA&nbsp;is a clinical-stage biopharmaceutical
company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer&rsquo;s disease,
Parkinson&rsquo;s disease, and NeuroOrphan indications driven by misfolded proteins. The Company&rsquo;s two clinically validated technology
platforms, SupraAntigen<SUP>&reg;</SUP>&nbsp;and Morphomer<SUP>&reg;</SUP>, fuel its broad and diversified pipeline of first- and best-in-class
assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials
and one of which is in Phase 3.&nbsp;AC Immune&nbsp;has a strong track record of securing strategic partnerships with leading global pharmaceutical
companies including&nbsp;Genentech, a member of the Roche Group, Eli Lilly and Company, and&nbsp;others, resulting in substantial non-dilutive
funding to advance its proprietary programs and &gt;$3&nbsp;billion&nbsp;in potential milestone payments.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">SupraAntigen<SUP>&reg;</SUP>&nbsp;is a registered
trademark of&nbsp;AC Immune SA&nbsp;in the following territories: AU, EU, CH, GB, JP, RU, SG and&nbsp;USA. Morphomer<SUP>&reg;</SUP>&nbsp;is
a registered trademark of&nbsp;AC Immune SA&nbsp;in CN, CH, GB, JP, KR, NO and RU.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The information on our website and any other websites
referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>Head of Investor Relations &amp; Corporate Communications</B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Gary Waanders, Ph.D., MBA</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">AC Immune</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Phone: +41 21 345 91 91</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Email: <FONT STYLE="color: Blue"><U>gary.waanders@acimmune.com</U></FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P></TD>
    <TD STYLE="width: 54%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>U.S. Investors</B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Corey Davis, Ph.D.</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">LifeSci Advisors</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Phone: +1 212 915 2577</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Email: <FONT STYLE="color: Blue"><U>cdavis@lifesciadvisors.com</U></FONT></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><B>International Media</B></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Chris Maggos</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Cohesion Bureau</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Phone: +41 79 367 6254</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">Email: <FONT STYLE="color: Blue"><U>chris.maggos@cohesionbureau.com</U></FONT></P></TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Forward looking statements</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This press release contains statements that constitute
&ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future
operating, financial or business performance or AC Immune&rsquo;s strategies or expectations. In some cases, you can identify these statements
by forward-looking words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;projects,&rdquo;
&ldquo;potential,&rdquo; &ldquo;outlook&rdquo; or &ldquo;continue,&rdquo; and other comparable terminology. Forward-looking statements
are based on management&rsquo;s current expectations and beliefs and involve significant risks and uncertainties that could cause actual
results, developments</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> / 4&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">and business decisions to differ materially from
those contemplated by these statements. These risks and uncertainties include those described under the captions &ldquo;Item 3. Key Information
&ndash; Risk Factors&rdquo; and &ldquo;Item 5. Operating and Financial Review and Prospects&rdquo; in AC Immune&rsquo;s Annual Report
on Form 20-F and other filings with the&nbsp;Securities and Exchange Commission. These include: the impact of Covid-19 on our business,
suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made,
and&nbsp;AC Immune&nbsp;does not undertake any obligation to update them in light of new information, future developments or otherwise,
except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> / 4&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +E"3H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'2LKKOU_X)E*DNAMT55@O4DPK_*WZ&K5?24:].M'FINZ,&FMPHHHK804444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)--HJ6*WDF/R+QZGI7ST8SJSLKMLVT2(J>D4DIPBDUH16$:<O\Y_2K0  P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3(HS)%\P]QW'^?2NW 5_95;/9GNX>?)*W1G(T445],>H%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !75> _$
M?]A:ZL<SXLKK$<N3PI_A;\#^A-<K151DXNZ,:]&-:FZ<]F?3E%<MX!UTZUX;
MC65LW-IB&7/4@#Y6_$?J#74UZ<9*2NC\WKTI4:DJ<MT%%%%49!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%(S!%+,< =:3:2NP&RRK#&7;\O6L>
M65II"[?EZ4^XG,\F>BCH*AKX[,<>\1/DA\*_'S_R.J$.75A5ZSM=V)9!Q_"/
M6H[.V\UM[CY!^M:E=>5Y?SVKU5IT7ZDU)VT04445].<X4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 95\FVY)_O#-5JOZDO,;?450
MKX7,8<F*FEWO]^IUP=XH****X2PK%UG5/*!M8&^<_?8?P^WUJSJVHBRAV1D>
M>XX_V1ZURI))))))ZDU+9Z6#PW-^\GMT$HHHJ3V HHHH **** *.L0^?I<ZX
MY4;Q^'-<77H+*'0JW0C!K@)$,<C(>JD@U[N5SO&4#OPLM&AM%%%>P=@4444
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M_P ?\*E3XH]!)I'U*W']-M.P'H=%<1!\3--? GLKJ/\ W-K#^8K7M/&N@79
M%^L3>DRE/U/'ZT@.@HJ.&>&YC$D$L<J'HR,&'YBI* "BBB@ HHHH **** "B
MBB@ HHHH ***P+SQGHEA>2VMQ<NLT3;7 B8X/UQ0!OT5S/\ PGWA[_G[D_[\
MM_A6OI.LV6MP//8R-)&C;&)4KSC/?ZT 7Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]]/=S']Y,Y<^V3TJO5""O5_AWJGVS0VLG;,MHV!G^XW(_7(_*O**Z'P7JO\
M9?B2 NV(;C]S)Z<]#^>/UH8'LU%%%2,**** "BBB@ HHHH **** "BBB@ HH
MKF_$GC"ST%3"F+B](XB4\+[L>WTZT ;US=6]G T]S,D,2]7=L"N'U?XDPQ%H
MM)M_.;IYTV0OX+U/XXKAM5UJ_P!:N?.O9R^/NH.%3Z"L^G81IZEXBU;521=W
MLK(?^6:G:GY#BLRBBF 45>M=%U.^ -MI]S*I_B6,X_/I6I%X&\12C/V#8/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF2OY<3/Z"IE)1BY/9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ1Z@FH:L:?\ \A*U_P"NR?S%4(]TLM+L-.4+9V<,'NB $_4]35NBBI&%%%%
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M4'IST/X'],U[-7SQ7NV@WQU+0;*[)RTD0WG_ &AP?U!I,9HT444@"N9\??\
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MC2N[(Y/5+C[3J4T@/RAMJ_0<5Z_\/?#0T71Q>7"8O;M0S9ZHG9?ZG_ZU>?\
M@'P]_;FOK),FZTM,2RY'#'^%?Q//T!KW&OO,)14(KRT1Y^=XOE2PL/G^B_4*
M***[CY8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ?NG\^/Q--B/8J***D84444 %>#ZXYDU_47/\5U(>O\ M&O>*\%U?_D-7_\
MU\2?^A&F@*5>M?#J,)X7W#^.X=C^0']*\EKV#P!C_A$K?&,[WSC_ 'C0Q'3T
M444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>(^+/^1KU+_KL?Y"O;J\1\6?\C7J7_78_P A30&-7J'PR_Y MY_U\?\
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MT444AA7,^/O^11N?]^/_ -"%=-7,^/O^11N?]^/_ -"% 'CU6-/_ .0E:_\
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MDX\]_<MT_3%>.VD!NKR"W7[TLBH/J3BO?T18T5$&%4  #L*& ZBBBD,****
M"BBB@ HHHH YSQOI0U/PY,RKF:V_?)ZX'WA^6?R%>-U]#,H92K $$8(/>O!-
M4LSI^JW=H?\ EC*R#W /!_*FA%:-VBD61&*NI#*1V(KWK3+U=1TNUO%Z31*Y
M'H2.1^=>!UZW\.[LW'A@0D\V\S(/H?F_J:&!UE%%%(84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %5KYMMJ1_>(%6:H:DW$:
M_4UPYA4Y,--^5OOT+@KR10HHHKX4ZPHHHH V+5MUK&?;%354T]\PLO\ =-6Z
M^^P<_:8>$O)?Y?H<<E:3"BBBNHD**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *;)(L:%V. *5F"*68X ZFLFYN#._H@Z"O/QV-CA8?WGLO
MU]"X0YF,FF:>0LWX#TJ.BBOB9SE.3E)W;.M*QRFMR^9J;CL@"C^?]:SJEN9/
M-NI9/[SD_K458GTU*/+!1\@HHHH- HHHH **** "BBB@ HHHH *YSQ)=;GBM
M5/3YV^O;^M=#(ZQ1M(YPJ@DGVK*\':<?$?C*.29<PQ'[1*#TPN-H_/ ^F:]7
M*Z#J5>;M^9K"4:<95I;15SU#P7H8T+PY!"ZXN9AYT^>NXCI^ P/P-=#117VR
M22LCX:K5E5FZDMV%%%%,S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH Y+XD7GV7P;<)G#7$B1#\]Q_137B%>E?%K4,SZ?IJ
MG[JM.X^ORK_)J\UKSZ[O,^ZR6ER81-_:;?Z?H%2VMM+>7<-M"NZ69Q&@]23@
M5%7>?"_1?MFM2:G*N8K-<)GO(W _(9_,5E"/-)(]#%5UAZ,JKZ?GT/5=,L(]
M+TNVL8ON01A ?7 Y/XGFK=%%>KL?FTI.3<GNPHHHH$%%%% !1110 4444 %<
M;\1=5^R:*EBC8DNV^;']Q>3^N/UKLJ\8\9ZI_:GB2X96S#!^YC^B]3^>:: Y
M^M#0]-;5M:M;(9VR.-Y'91RQ_(&L^O0_AGI>3=:HZ]/W,7\V/\OUIB/0U540
M*H 51@ =A2T5C>)/$$?AW3EN6A\YW<(D>_;GN3G!Z5(S9HKSS_A:7_4&_P#)
MK_["C_A:7_4&_P#)K_["G8#T.BO//^%I?]0;_P FO_L*/^%I?]0;_P FO_L*
M+ >AUF^(--&KZ'=V>!O=,Q^SCD?J*X[_ (6E_P!0;_R:_P#L*/\ A:7_ %!O
M_)K_ .PHL!YX05)!!!'!!H5BK!E)!!R".U6M3NX[_4[B[B@\A)G+^7NW;2>3
MS@=\U4IB/=M!U)=7T2UO01N=,./1QPWZBM&O.?AIJNV2ZTJ1N&_?19]>C#^1
M_ UZ-4C"BBB@ KP?7$,>OZBA_ANI!T_VC7O%>*>,(/L_BS44QUD#_P#?0!_K
M30&'7K7PZ</X7VC^"=U/Z'^M>2UZ9\,;C=IU_;9Y259,?[PQ_P"RT,1W=%%%
M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M->I?]=C_ "%8U;/BS_D:]2_Z['^0K&JA'J'PR_Y MY_U\?\ LHKMZXCX9?\
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M_P \W _,'^E>>5VOPS<C7KJ/G#6Q;\F7_&FQ'J5%%%2,**** "BBB@ HHHH
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M_;3_ ,>_PH_X5EJ?_/[:?^/?X47 XBBNW_X5EJ?_ #^VG_CW^%'_  K+4_\
MG]M/_'O\*+@<117;_P#"LM3_ .?VT_\ 'O\ "N0O[*73K^>SF \R%RC8Z''<
M>U $VCZ@VE:O:WRY_=2 L!W7H1^1->[QR)+&DD;!D<!E([@U\]5Z[X U3[?X
M>6W=LRV9\L_[O53_ #'X4F!U5%%%(85Y5\2+4P^((K@#Y9X!S_M*2#^F*]5K
MB_B38>?HD%XHRUM+@^RMQ_,+30'EE=E\-[P0>();9C@7$) 'JR\_RW5QM7-)
MOFTS5K6]7/[F0,0.X[C\1D4Q'O=%-CD26-)(V#(X#*1W!IU2,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ'Q9_R->I?]
M=C_(5[=7B/BS_D:]2_Z['^0IH#&KU#X9?\@6\_Z^/_917E]>H?#+_D"WG_7Q
M_P"RBAB.WHHHI#"N=\=?\B;?_P#;/_T8M=%7.^.O^1-O_P#MG_Z,6@#QJK&G
M_P#(2M?^NR?S%5ZL:?\ \A*U_P"NR?S%4(]_HHHJ1A1110 4444 %%%% $=Q
M_P >TO\ N'^5?/E?0=Q_Q[2_[A_E7SY30@KV[PE_R*FF_P#7$?S->(U[=X2_
MY%33?^N(_F:&!LT444AA1110 4444 %%%% 'B/BS_D:]2_Z['^0K&K9\6?\
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M9/1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMUV)_OM_@,_G7#U[9X2TO^R?#EK"RXED'FR_[S<X_ 8'X4,1MT444AA1110
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M0^&7_(%O/^OC_P!E%>7UZA\,O^0+>?\ 7Q_[**&([>BBBD,*YWQU_P B;?\
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ME18#W:BF12)-$DL;!HW4,K#H0>AI](84444 %%%% !1110 4444 %>(^+/\
MD:]2_P"NQ_D*]NKQ'Q9_R->I?]=C_(4T!C5ZA\,O^0+>?]?'_LHKR^O4/AE_
MR!;S_KX_]E%#$=O1112&%<[XZ_Y$V_\ ^V?_ *,6NBKG?'7_ ")M_P#]L_\
MT8M 'C56-/\ ^0E:_P#79/YBJ]6-/_Y"5K_UV3^8JA'O]%%%2,**** "BBB@
M HHHH CN/^/:7_</\J^?*^@[C_CVE_W#_*OGRFA!7MWA+_D5--_ZXC^9KQ&O
M;O"7_(J:;_UQ'\S0P-FBBBD,**** "BBB@ HHHH \1\6?\C7J7_78_R%8U;/
MBS_D:]2_Z['^0K&JA'J'PR_Y MY_U\?^RBNWKB/AE_R!;S_KX_\ 917;U(PH
MHHH YGQ]_P BC<_[\?\ Z$*\>KV'Q]_R*-S_ +\?_H0KQZFA%C3_ /D)6O\
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MVUF5%+,0%'4D\"N<U?QOH^EJRI,+N<=(X#D9]VZ#]3[5Y)<W]Y>?\?5W//\
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M#\#R?P%=?I?PUM82LFIW+7#=XHOE7\3U/Z5W=%%QD=O!%:V\<$"!(HU"HH[
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MD&4\A3Z5[510!\^?9YO^>,G_ 'R:].^&B.FBW8=2I^T=QC^$5VM%.X!1112
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M(O(&?XWKCOL\W_/&3_ODU]!T4[@>8_#2*1-:NRZ,H^S]QC^(5Z=112 ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_,[G_.![57K@J57/3H?:X#+*>%7,]9]^WH%=+X2\'W7B:ZWG,-A&V)9L=?\
M97U/\OT-OP?X&N-?D6\O T&F@_>Z-+[+[>_Y>WLUK:P65K';6L2Q0QC:B*,
M"KI4>;66QS9GFRHWI47>7?M_P?R&V-C;:;916=G$L4$0PJK_ )Y/O5BBBNX^
M,;<G=[A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!!+:0R\E=I]5XJI)I[CE&#
M#T/!K2HK@KY?AZVLHV?=:%J<D8KP2Q_>1A[XJ.MZF-#&_P!Y%/X5Y53(_P#G
MW/[U_D:*KW1B45K-90'^#'T-,.GPGHSC\:Y)9-B5M9_/_@%>UB9E%:)TY.SM
M1_9R?\]&_*L_[)Q7\J^]#]I$SJ*TAIT7=G_2GBP@'4$_4U<<FQ+WLOF+VL3*
MI0"3@ D^U;"VT*](U_'FI  HP  /:NF&1S^W-?)"=5=$9"6D[](R/KQ5A-./
M\;@>PK0HKOI9/AX?%>7K_P  AU9,@CLX8_X-Q]6YJ?I117J4Z5.FK0BD9MM[
MA1116@@HHHH **** "BBB@ HHHH **** "BBB@"O>6%IJ,!@O+:*XB/\,BAA
M7$ZK\+-,NBSZ=<2V;G^!OWB?KR/S-=]142A&6Z.FABZ]!_NI-?E]QX=J7P[\
M0Z>6*6RW<8_BMVR?^^3@_I7-7%I<V<GEW-O+ _\ =E0J?R-?2U,EABGC,<T:
M2(>JNH(/X&L)89=&>U2S^K'2I%/TT_S1\S45] 77@[P[>$F72+8$]3&OE_\
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MHPC'9'DUL;B*_P#$FW^7W!1115G(%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
